10月10日，利德曼盘中上涨2.01%，截至10:38，报7.61元/股，成交4721.55万元，换手率1.15%，总市值 41.40亿元。 资金流向方面，主力资金净流入293.52万元，特大单买入142.01万元，占比3.01%，卖出0.00元，占比 0.00%；大单买入848.17万元，占比17.96%，卖出696.67万元，占比14.76%。 利德曼今年以来股价涨55.31%，近5个交易日跌0.13%，近20日跌3.79%，近60日涨41.19%。 利德曼所属申万行业为：医药生物-医疗器械-体外诊断。所属概念板块包括：基因测序、辅助生殖、体 外诊断、冷链物流、小盘等。 截至9月19日，利德曼股东户数3.35万，较上期减少4.99%；人均流通股16192股，较上期增加5.26%。 2025年1月-6月，利德曼实现营业收入1.60亿元，同比减少14.80%；归母净利润-424.52万元，同比减少 800.43%。 分红方面，利德曼A股上市后累计派现1.43亿元。近三年，累计派现544.01万元。 机构持仓方面，截止2025年6月30日，利德曼十大流通股东中，金元顺安元启灵活配置混合（004685） 位居第八 ...

证券日报网讯安科生物（300009）9月30日在互动平台回答投资者提问时表示，公司已布局辅助生殖领 域多年，产品涵盖上游生殖检测至下游治疗药物，并于两年前正式成立单独的生殖及抗病毒事业部对市 场进行细分推广。本次与宝济药业的独家代理合作，旨在充分发挥双方优势资源，实现强强联合的协同 效应。公司生殖及抗病毒事业部已有超过300人的专职团队，待长效促卵泡素正式投向市场以后，计划 依托现有团队开展Ⅳ期临床试验、各类学术活动、科研项目、公益项目等多维度市场推广工作。预计 2026年度该产品将贡献规模性收入。与维昇药业合作的隆培促生长素目前正在报产审评中。公司期待长 效生长激素和长效促卵泡素可以快速投入市场，为公司的经营业绩提供新的增长点。 ...

资料显示，健康元药业集团股份有限公司位于广东省深圳市南山区高新区北区朗山路17号健康元药业集 团大厦，成立日期1992年12月18日，上市日期2001年6月8日，公司主营业务涉及公司属于综合性制药企 业,主要从事中药、保健品及西药的研究、开发及生产经营。主营业务收入构成为：化学制剂47.71%， 化学原料药及中间体31.97%，中药制剂10.28%，诊断试剂及设备4.74%，保健食品3.08%，生物制品 1.20%，其他(补充)0.86%，其他0.15%。 健康元所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：创新药、AI医药、原料 药、中药、辅助生殖等。 截至6月30日，健康元股东户数7.63万，较上期减少4.32%；人均流通股23991股，较上期增加4.52%。 2025年1月-6月，健康元实现营业收入78.98亿元，同比减少4.08%；归母净利润7.85亿元，同比增长 1.10%。 分红方面，健康元A股上市后累计派现39.79亿元。近三年，累计派现10.40亿元。 机构持仓方面，截止2025年6月30日，健康元十大流通股东中，香港中央结算有限公司位居第二大流通 股东，持股6837.85万 ...

异动分析 医疗器械概念+辅助生殖+人民币贬值受益 来源：新浪证券-红岸工作室 9月26日，采纳股份跌1.25%，成交额4813.76万元，换手率2.60%，总市值29.90亿元。 1、公司主营业务为从事注射穿刺器械及实验室耗材的研发、生产和销售。公司目前主要产品为穿刺 针、注射器、实验室耗材及口罩等。 2、公司采纳医疗于2018年开始向Thermo Fisher 供应试管婴儿培育管产品。 3、根据2024年年报，公司海外营收占比为90.61%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-187.34万，占比0.04%，行业排名70/131，连续2日被主力资金减仓；所属行业主力净流 入-6.04亿，当前无连续增减仓现象，主力趋势不明显。 区间今日近3日近5日近10日近20日主力净流入-187.34万-741.67万-2607.78万-4266.65万-4035.66万 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额3092.47万，占总成交额的8.28%。 技术面：筹码平均交易成本为23.47元 该股筹码平均交易成本为23 ...

资金流向方面，主力资金净流入821.61万元，大单买入2255.90万元，占比20.87%，卖出1434.29万元， 占比13.27%。 麦迪科技今年以来股价涨45.62%，近5个交易日涨1.15%，近20日涨0.34%，近60日跌6.96%。 今年以来麦迪科技已经8次登上龙虎榜，最近一次登上龙虎榜为3月10日，当日龙虎榜净买入3115.92万 元；买入总计1.15亿元 ，占总成交额比8.31%；卖出总计8361.32万元 ，占总成交额比6.06%。 9月25日，麦迪科技盘中上涨2.18%，截至13:41，报14.97元/股，成交1.08亿元，换手率2.38%，总市值 45.85亿元。 资料显示，苏州麦迪斯顿医疗科技股份有限公司位于江苏省苏州工业园区归家巷222号，成立日期2009 年8月14日，上市日期2016年12月8日，公司主营业务涉及提供临床医疗管理信息系统(CIS)系列应用软 件和临床信息化的整体解决方案。主营业务收入构成为：自制软件40.39%，运维服务31.55%，医疗服 务21.12%，整体解决方案4.60%，外购软硬件1.95%，其他0.40%。 责任编辑：小浪快报 截至6月30日，麦迪科技 ...

Core Viewpoint - Zhejiang Medicine's stock price has shown a decline of 7.58% year-to-date, with a recent increase of 2.07% on September 24, 2023, indicating potential volatility in the market [1]. Financial Performance - For the first half of 2025, Zhejiang Medicine reported a revenue of 4.323 billion yuan, a year-on-year decrease of 1.87%, while the net profit attributable to shareholders was 673 million yuan, reflecting a significant increase of 113.52% [2]. - Cumulative cash dividends since the company's A-share listing amount to 4.377 billion yuan, with 661 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 65,500, with an average of 14,674 circulating shares per person, a decrease of 0.55% [2]. - The top circulating shareholder, Hong Kong Central Clearing Limited, holds 71.2904 million shares, an increase of 34.9417 million shares compared to the previous period [3].

9月24日，麦迪科技盘中上涨2.34%，截至13:03，报14.45元/股，成交5340.48万元，换手率1.23%，总市 值44.26亿元。 截至6月30日，麦迪科技股东户数3.63万，较上期减少24.87%；人均流通股8429股，较上期增加 33.09%。2025年1月-6月，麦迪科技实现营业收入1.35亿元，同比减少47.24%；归母净利润2832.75万 元，同比增长137.11%。 分红方面，麦迪科技A股上市后累计派现7135.67万元。近三年，累计派现0.00元。 机构持仓方面，截止2025年6月30日，麦迪科技十大流通股东中，鹏华碳中和主题混合A（016530）位 居第八大流通股东，持股219.36万股，为新进股东。 责任编辑：小浪快报 今年以来麦迪科技已经8次登上龙虎榜，最近一次登上龙虎榜为3月10日，当日龙虎榜净买入3115.92万 元；买入总计1.15亿元 ，占总成交额比8.31%；卖出总计8361.32万元 ，占总成交额比6.06%。 资料显示，苏州麦迪斯顿医疗科技股份有限公司位于江苏省苏州工业园区归家巷222号，成立日期2009 年8月14日，上市日期2016年12月8日，公司主营业务 ...

Group 1 - The share transfer of Shangwei New Materials has been completed, with the controlling shareholder changing to Zhiyuan Hengyue, a holding platform established by Zhiyuan Robotics [1] - Zhiyuan Hengyue and Zhiyuan Xinchuang Partnership now collectively hold 29.99% of the shares and corresponding voting rights in the listed company [1] Group 2 - Dongshan Precision is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international strategy and brand recognition [2] - The details of the H-share issuance are still under discussion with relevant intermediaries [2] Group 3 - Walden Materials' subsidiary, Shanghai Kote, plans to invest up to 1 billion yuan in a new materials project in Suzhou, focusing on high-performance products for battery thermal runaway protection and electronic components [3] - The investment will be allocated to infrastructure, equipment, and working capital, with respective amounts of approximately 360 million yuan, 240 million yuan, and 400 million yuan [3] Group 4 - Hengrui Medicine's SHR7280 tablet application for market approval has been accepted by the National Medical Products Administration, targeting controlled ovarian stimulation in assisted reproductive technology [4] - The total R&D investment for SHR7280 has reached approximately 264 million yuan [4] Group 5 - Hualing Cable intends to acquire control of Anhui San Bamboo Intelligent Technology for no more than 270 million yuan, aiming to expand into robotics and high-frequency transmission sectors [5] - The acquisition is expected to enhance the company's integrated solution capabilities [5] Group 6 - Dongcheng Pharmaceutical's 225Ac-LNC1011 injection has received approval for clinical trials for prostate cancer, with no similar products currently on the market [6] - The project has incurred R&D expenses of approximately 14.53 million yuan [6] Group 7 - Baijin Medical's radiofrequency ablation system has entered the special review process for innovative medical devices, which is expected to expedite its registration [7][8] - The system is designed for treating atrial fibrillation and features advanced technology [7] Group 8 - Sinovac Biotech's human interferon α1b inhalation solution has been included in the list of breakthrough therapeutic varieties by the National Medical Products Administration, targeting respiratory infections in children [9] - The drug is currently in phase III clinical trials [9] Group 9 - Chao Xun Communication's board members have completed their share reduction plan, with specific shares sold by directors and supervisors [10] - The reduction percentages were minimal, indicating a controlled approach to shareholding changes [10] Group 10 - Several companies, including China West Electric and Pinggao Electric, have won significant contracts from the State Grid, with total amounts reaching 1.64 billion yuan and 1.369 billion yuan respectively [11] - These contracts reflect ongoing infrastructure investments in the power sector [11]

恒瑞医药晚间公告，近日公司收到国家药品监督管理局下发的《受理通知书》，公司SHR7280片的药品 上市许可申请获国家药监局受理。SHR7280片是一种口服小分子GnRH受体拮抗剂，可以阻断内源性 GnRH与GnRH受体的结合，抑制LH等促性腺激素的合成和释放，用于辅助生殖技术的控制性超促排卵 治疗。国内外辅助生殖领域尚无口服GnRH拮抗剂获批上市。 ...

Group 1 - The stock price of Lizhu Group fell by 2.01% on September 23, reaching 37.95 CNY per share, with a trading volume of 1.58 billion CNY and a turnover rate of 0.71%, resulting in a total market capitalization of 34.31 billion CNY [1] - Year-to-date, Lizhu Group's stock price has increased by 2.79%, but it has decreased by 5.88% in the last five trading days and by 9.15% in the last 20 days, while it has risen by 3.83% over the last 60 days [1] - As of June 30, 2025, Lizhu Group's revenue was 6.272 billion CNY, a year-on-year decrease of 0.17%, while the net profit attributable to shareholders was 1.281 billion CNY, reflecting a year-on-year increase of 9.40% [2] Group 2 - Lizhu Group's main business revenue composition includes chemical preparations (52.14%), APIs and intermediates (26.49%), traditional Chinese medicine preparations (12.75%), diagnostic reagents and equipment (5.97%), and biological products (1.51%) [2] - The company has distributed a total of 10.523 billion CNY in dividends since its A-share listing, with 3.721 billion CNY distributed in the last three years [3] - As of June 30, 2025, the number of shareholders in Lizhu Group was 46,400, a decrease of 11.30% from the previous period, while the average circulating shares per person increased by 12.71% to 12,581 shares [2]